Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease

SOUTH SAN FRANCISCO, Calif., March 20, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, announced today that it will be presenting at the "Industry Colloquium: Novel Targets and Therapies in Liver Disease" a conference organized by the American Association for the Study of Liver Disease (AASLD). The conference is being held today and tomorrow, March 21^st, in Durham, NC.

"This is an exciting time in the development of novel therapies to treat patients suffering from NASH and liver fibrosis," commented Laurent Fischer, M.D., chairman and CEO of Tobira Therapeutics. "We look forward to presenting supportive new data and a program overview for cenicriviroc in NASH at such an important event for the hepatology community."

Tobira's cenicriviroc (CVC) presentations at AASLD's Industry Colloquium will include:

• Friday, March 20^th
  Lunch and Poster Session: 12:20 PM – 1:45 PM
  Oral, Dual CCR2/CCR5 Antagonist Cenicriviroc Leads To Dose-Dependent Decreases In Monocyte Recruitment In A Thioglycollate-Induced Model Of Peritonitis (Poster #8)
  F. Tacke; D. Poulin; H. Jenkins; G. Wolfgang; E. Lefebvre
• Saturday, March 21^st
  Session VII: NASH: Clinical Endpoints and Drug Development (II): 9:20 AM – 9:40 AM
  Cenicriviroc as Treatment for NASH in Patients with Liver Fibrosis
  Eric A. Lefebvre, MD – Chief Medical Officer, Tobira Therapeutics

About Tobira Therapeutics

Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV-1. The company's lead product, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV-1.  Tobira is actively enrolling patients in a Phase 2b clinical trial called CENTAUR to evaluate CVC in patients with NASH and liver fibrosis.  On January 14, 2015, Tobira and Regado Biosciences (NASDAQ: RGDO) entered into a merger agreement that is expected to close in the second quarter of 2015. Learn more about Tobira at www.tobiratherapeutics.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking information and forward-looking statements (collectively "forward-looking statements" within the meaning of applicable securities laws). Such statements, based as they are on the current expectations of management of Tobira Therapeutics and upon what management believes to be reasonable assumptions based on information currently available to it, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Tobira's control. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate" and other similar terminology, or state that certain actions, events or results "may" or "would" be taken, occur or be achieved.

Whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict. These risks include those inherent in drug development, whether Tobira will be able to obtain financing when needed or on favorable terms, and other risks described in Tobira's filings with the Securities and Exchange Commission. In evaluating any forward-looking statements in this release, Tobira cautions readers not to place undue reliance on any forward-looking statements. Unless otherwise required by applicable securities laws, Tobira does not intend, nor does it undertake any obligation, to update or revise any forward-looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise.

Tobira Contacts:

Chris Peetz
Chief Financial Officer
Tobira Therapeutics
(650) 351-5018
[email protected]

Mark Corbae
Canale Communications
(619) 849-5375
[email protected]

SOURCE Tobira Therapeutics, Inc.

Related Links

http://www.tobiratherapeutics.com/